227 related articles for article (PubMed ID: 16517966)
1. Prevalence and patterns of physiologic muscle uptake detected with whole-body 18F-FDG PET.
Jackson RS; Schlarman TC; Hubble WL; Osman MM
J Nucl Med Technol; 2006 Mar; 34(1):29-33. PubMed ID: 16517966
[TBL] [Abstract][Full Text] [Related]
2. Retro-orbital injection is an effective route for radiopharmaceutical administration in mice during small-animal PET studies.
Nanni C; Pettinato C; Ambrosini V; Spinelli A; Trespidi S; Rubello D; Al-Nahhas A; Franchi R; Alavi A; Fanti S
Nucl Med Commun; 2007 Jul; 28(7):547-53. PubMed ID: 17538396
[TBL] [Abstract][Full Text] [Related]
3. Tumor blood flow measured by PET dynamic imaging of first-pass 18F-FDG uptake: a comparison with 15O-labeled water-measured blood flow.
Mullani NA; Herbst RS; O'Neil RG; Gould KL; Barron BJ; Abbruzzese JL
J Nucl Med; 2008 Apr; 49(4):517-23. PubMed ID: 18344436
[TBL] [Abstract][Full Text] [Related]
4. Patterns of (18)F-FDG uptake in adipose tissue and muscle: a potential source of false-positives for PET.
Yeung HW; Grewal RK; Gonen M; Schöder H; Larson SM
J Nucl Med; 2003 Nov; 44(11):1789-96. PubMed ID: 14602861
[TBL] [Abstract][Full Text] [Related]
5. The value of quantifying 18F-FDG uptake in thyroid nodules found incidentally on whole-body PET-CT.
Bogsrud TV; Karantanis D; Nathan MA; Mullan BP; Wiseman GA; Collins DA; Kasperbauer JL; Strome SE; Reading CC; Hay ID; Lowe VJ
Nucl Med Commun; 2007 May; 28(5):373-81. PubMed ID: 17414887
[TBL] [Abstract][Full Text] [Related]
6. Impact of animal handling on the results of 18F-FDG PET studies in mice.
Fueger BJ; Czernin J; Hildebrandt I; Tran C; Halpern BS; Stout D; Phelps ME; Weber WA
J Nucl Med; 2006 Jun; 47(6):999-1006. PubMed ID: 16741310
[TBL] [Abstract][Full Text] [Related]
7. Increased (18)F-fluorodeoxyglucose uptake in benign, nonphysiologic lesions found on whole-body positron emission tomography/computed tomography (PET/CT): accumulated data from four years of experience with PET/CT.
Metser U; Even-Sapir E
Semin Nucl Med; 2007 May; 37(3):206-22. PubMed ID: 17418153
[TBL] [Abstract][Full Text] [Related]
8. Optimizing imaging protocols for overweight and obese patients: a lutetium orthosilicate PET/CT study.
Halpern BS; Dahlbom M; Auerbach MA; Schiepers C; Fueger BJ; Weber WA; Silverman DH; Ratib O; Czernin J
J Nucl Med; 2005 Apr; 46(4):603-7. PubMed ID: 15809482
[TBL] [Abstract][Full Text] [Related]
9. Optimized contrast-enhanced CT protocols for diagnostic whole-body 18F-FDG PET/CT: technical aspects of single-phase versus multiphase CT imaging.
Brechtel K; Klein M; Vogel M; Mueller M; Aschoff P; Beyer T; Eschmann SM; Bares R; Claussen CD; Pfannenberg AC
J Nucl Med; 2006 Mar; 47(3):470-6. PubMed ID: 16513616
[TBL] [Abstract][Full Text] [Related]
10. Comparison of lesion-to-cerebellum uptake ratios and standardized uptake values in the evaluation of lung nodules with 18F-FDG PET.
Obrzut S; Pham RH; Vera DR; Badran K; Hoha CK
Nucl Med Commun; 2007 Jan; 28(1):7-13. PubMed ID: 17159543
[TBL] [Abstract][Full Text] [Related]
11. Role of whole body positron emission tomography/computed tomography scan with 18F-fluorodeoxyglucose in patients with biopsy proven tumor metastases from unknown primary site.
Pelosi E; Pennone M; Deandreis D; Douroukas A; Mancini M; Bisi G
Q J Nucl Med Mol Imaging; 2006 Mar; 50(1):15-22. PubMed ID: 16557200
[TBL] [Abstract][Full Text] [Related]
12. The feasibility of 11C-methionine-PET in diagnosis of solitary lung nodules/masses when compared with 18F-FDG-PET.
Hsieh HJ; Lin SH; Lin KH; Lee CY; Chang CP; Wang SJ
Ann Nucl Med; 2008 Jul; 22(6):533-8. PubMed ID: 18670862
[TBL] [Abstract][Full Text] [Related]
13. Tissue distribution of 18F-FDG-labeled peripheral hematopoietic stem cells after intracoronary administration in patients with myocardial infarction.
Kang WJ; Kang HJ; Kim HS; Chung JK; Lee MC; Lee DS
J Nucl Med; 2006 Aug; 47(8):1295-301. PubMed ID: 16883008
[TBL] [Abstract][Full Text] [Related]
14. Physiologic thymic uptake of 18F-FDG in children and young adults: a PET/CT evaluation of incidence, patterns, and relationship to treatment.
Jerushalmi J; Frenkel A; Bar-Shalom R; Khoury J; Israel O
J Nucl Med; 2009 Jun; 50(6):849-53. PubMed ID: 19443604
[TBL] [Abstract][Full Text] [Related]
15. Imaging of inflamed and vulnerable plaque in coronary arteries with 18F-FDG PET/CT in patients with suppression of myocardial uptake using a low-carbohydrate, high-fat preparation.
Wykrzykowska J; Lehman S; Williams G; Parker JA; Palmer MR; Varkey S; Kolodny G; Laham R
J Nucl Med; 2009 Apr; 50(4):563-8. PubMed ID: 19289431
[TBL] [Abstract][Full Text] [Related]
16. F-18 FDG PET/CT in the management of thyroid cancer.
Iagaru A; Kalinyak JE; McDougall IR
Clin Nucl Med; 2007 Sep; 32(9):690-5. PubMed ID: 17710020
[TBL] [Abstract][Full Text] [Related]
17. Technologist radiation exposure in routine clinical practice with 18F-FDG PET.
Guillet B; Quentin P; Waultier S; Bourrelly M; Pisano P; Mundler O
J Nucl Med Technol; 2005 Sep; 33(3):175-9. PubMed ID: 16145226
[TBL] [Abstract][Full Text] [Related]
18. Prospective evaluation of physiologic uptake detected with true whole-body 18F-FDG PET/CT in healthy subjects.
Reinking MF; Osman MM
J Nucl Med Technol; 2009 Mar; 37(1):31-7. PubMed ID: 19223428
[TBL] [Abstract][Full Text] [Related]
19. First clinical experience with integrated whole-body PET/MR: comparison to PET/CT in patients with oncologic diagnoses.
Drzezga A; Souvatzoglou M; Eiber M; Beer AJ; Fürst S; Martinez-Möller A; Nekolla SG; Ziegler S; Ganter C; Rummeny EJ; Schwaiger M
J Nucl Med; 2012 Jun; 53(6):845-55. PubMed ID: 22534830
[TBL] [Abstract][Full Text] [Related]
20. Whole-body radiation dosimetry of 2-[18F]Fluoro-A-85380 in human PET imaging studies.
Obrzut SL; Koren AO; Mandelkern MA; Brody AL; Hoh CK; London ED
Nucl Med Biol; 2005 Nov; 32(8):869-74. PubMed ID: 16253812
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
